Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-06
1998-11-17
Jagannathan, Vasu S.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530350, A61K 3800, C07K 100
Patent
active
058376780
ABSTRACT:
The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administration of bactericidal/permeability-increasing (BPI) protein products.
REFERENCES:
patent: 5086164 (1992-02-01), Maione et al.
patent: 5112946 (1992-05-01), Maione
patent: 5171739 (1992-12-01), Scott et al.
Azizkhan et al., "Mast Cell Heparin Stimulates Migration of Capillary Endothelial Cells in Vitro", J. Exp. Med., 152:931-944 (Oct. 1980).
Castellot et al., "Heparin Potentiation of 3T3-Adipocyte Stimulated Angiogensis: Mechanism of Action on Endothelial Cells", J. Cell. Phys., 127:328-329 (1986).
Cook et al., "Platelet Factor 4 Efficiently Reverses Heparin Anticoagulation in the Rat Without Adverse Effects of Heparin-Protamine Complexes", Circulation, 85(3): 1102-1109 (Mar. 1992).
Elsbach and Weiss, "Oxygen-Independent Antimicrobial Systems of Phagocytes", Chapter 30, pp. 603-636 in Inflammation: Basic Principles and Correlates, 2nd. Ed., Review Press, Ltd., (1992).
Elsbach et al., "Separation and Purification of a Potent Bactericidal/Permeability-Increasing Protein and a Closely Associated Phospholipase A.sub.2 From Rabbit Polymorphonuclear Leukocytes", J. Biol. Chem., 254(21): 11000-11009 (Nov. 10, 1979).
Folkman and Brem, "Abiogensis and Inflammation", Chapter 40, pp. 821-839 in Inflammation: Basic Principles and Correlates, 2nd Ed., Review Press, Ltd., (1992).
Gallagher, "Heparan Sulphates as Membrane Receptors for the Fibroblast Growth Factors", Eur. J. Clin. Chem. Clin. Biochem., 32(4):239-247 (1994).
Gammon et al., "T Cell Determinant Structure: Cores and Determinant Envelopes in Three Major Mouse Histocompatibility Complex Halotypes", J. Exp. Med., 173:609-617 (Mar. 1991).
Garcia, "Repligen IND for Platelet Factor", BioWorld Today, p. 5 (Jan. 11, 1983).
Gazzano-Santoro et al., "High Affinity Binding of the Bactericidal/Permeability Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide", Infect. Immunol., 60(11):4754-4761 (Nov. 1992).
Gray et al., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein", J. Biol. Chem., 264(16):9505-9509 (Jun. 5, 1989).
Heyderman et al., "Reduction of the Anticoagulant Activity of Glycosaminoglycans on the Surface of the Vascular Endothelium by Endotoxin and Neutrophils: Evaluation by an Amidolytic Assay", Thrombosis Res., 67:677-685 (Apr. 28, 1992).
Hiti-Harper et al., "Platelet Factor 4: An Inhibitor of Collagenase", Science, 199:991-992 (Mar. 3, 1978).
Kaklamanis, "Experimental Animal Models Resembling Rheumatoid Arthritis", Clin. Rheumatol., 11(1):41-47 (Abstract) (1992).
Little et al., "Functional Domains of Recombinant Bactericidal/Permeability Increasing Protein (rBPI.sub.23) ", J. Biol. Chem., 269(3):1865-1872 (Jan. 1994).
Maeji et al., "Multi-pin peptide strategy for T Cell determinant analysis", J. Immunol. Meth., 134:23-33 (1990).
Maione et al., "Inhibition of Tumor Growth in Mice by an Analogue of Platelet Factor 4 That Lacks Affinity for Heparin and Retains Potent Angiostatic Activity", Cancer Res., 51:2077-2083 (Apr. 15, 1991).
Maione et al., CAS BioTech Updates-Antibody Conjugates, p. 1, 1334, 117:226303x (Jun. 16, 1992).
Mannion et al., "Separation of Sublethal and Lethal Effects of the Bactericidal/Permeability Increasing Protein on Escherichia coli", J. Clin. Invest., 85:853-860 (Mar. 1990).
Marra et al., "The Role of Bactericidal/Permeability-Increasing Protein as a Natural Inhibitor of Bacterial Endotoxin", J. Immunol., 148(2):532-537 (Jan. 15, 1992).
Marra et al., Aug. 23, 1990 (Abstract: WPI Acc No.:90-274947/36).
Merrifield, "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide",J. Am. Chem. Soc., 85:2149-2154 (Jul. 20, 1963).
Merrifield et al., "Instrument for Automated Synthesis of Peptides", Anal. Chem., 38(13): 1905-1914 (Dec. 1966).
Miles et al., "Recombinant Platelet Factor 4 (rPF4) and a Non-Heparin Binding Derivative Inhibit AIDS-Kaposi Sarcoma Derived Cell Lines", VII International Conference on AIDS Held in Florence Italy, Paper 41(8), W.A. 1066 p. 108 (Jun. 16-21, 1991).
Mitchell and Wilks, "Inhibitors of Angiogenesis", Chapter 15, pp. 139-148 in Annual Reports in Medical Chemistry, vol. 27, Academic Press, Inc. (1992).
Murav'Ev, "Effect of heparin therapy on the clinical and laboratory indicators in rheumatoid arthritis", Ter. Ark., 52(11):126-129 (1980).
Ooi et al., "Endotoxin-neutralizing Properties of the 25 kD N-Terminal Fragment and a Newly Isolated 30 kD C-Terminal Fragment of the 55-60 kD Bactericidal/Permeability-increasing Protein of Human Neutrophils", J. Exp. Med,, 174:649-655 (Sep. 1991).
Passaniti et al., "Methods in Laboratory Investigation A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor", Lab. Invest., 67(4):519-528 (1992).
Peacock et al., "Angiobiogenesis Inhibition Suppresses Collagen Arthritis", J. Exp. Med., 175:1135-1138 (Apr. 1992).
Redini et al., "Inhibition of leucocyte elastase by heparin and its derivatives", Biochem. J., 252(2):515-519 (Abstract) (1980).
Repligen Corporation, Research in Review, (Spring 1992).
St. Charles et al., "The Three-Dimensional Structure of Bovine Platelet Factor 4 at 3.0-.ANG. Resolution", J. Biol. Chem., 264(4):2092-2099 (Feb. 5, 1989).
Stuart et al., "Nature and the Specificity of the Immune Response to Collagen in Type II Collagen-induced Arthritis in Mice", J. Clin. Invest., 69:673-683 (Mar. 1982).
Takayama et al., "Absence of Lipopolysaccharide in the Lyme Disease Spirochete, Borrelia burgdorferi", Infect. Immun., 55(9):2311-2312 (Sep. 1987).
Taylor and Folkman, "Protamine in an inhibitor of angiogenesis", Nature, 297:307-312 (May 27, 1982).
Tontsch and Bauer, "Isolation, Characterization, and Long-Term Cultivation of Porcine and Murine Cerebral Capillary Endothelial Cells", Microvascular Res., 37:148-161 (1981).
Vogel et al., "Modulation of Endothelial Cell Proliferation, Adhesion, and Motility by Recombinant Heparin-Binding Domain and Synthetic Peptides From the Type I Repeats of Thrombospondin", J. Cellular Biochem., 53:74-84 (1993).
Weiss and Olsson, "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils", Blood, 69(2): 652-659 (Feb. 1987).
Weiss et al., "Partial Characterization and Purification of a Rabbit Granulocyte Factor that Increase Permeability of Escherichia coli", J. Clin. Invest., 55:33-42 (Jan. 1975).
Weiss et al., "Purification and Characterization of a Potent Bactericidal and Membrane Active Protein from the Granules of Human Polymorphonuclear Leukocytes", J. Biol. Chem., 253(8):2664-2672 (Apr. 25, 1978).
Yayon et al., "Cell Surface, Heparin-Like Molecules are Required for Binding of Basic Fibroblast Growth Factor to Its High Affinity Receptor", Cell, 64:641-648 (Feb. 22, 1991).
Yong et al., "An experimental mouse model of Yersinia-induced reactive arthritis", Microbial Pathogenesis, 4:305-310 (1988).
Jagannathan Vasu S.
Kim Hyosuk
Xoma Corporation
LandOfFree
Therapeutic uses of bactericidal/permeability increasing protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic uses of bactericidal/permeability increasing protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic uses of bactericidal/permeability increasing protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-884481